title: Treatment Strategy for Non-Responders to PDE5 Inhibitors.
abstract: Currently, phosphodiesterase type 5 (PDE5) inhibitors are the initial treatment option for erectile dysfunction. The reported efficacy of PDE5 inhibitors is about 70%, although it is significantly lower in difficult-to-treat subpopulations. Treatment failures might be due to the severity of the underlying pathophysiology, improper use of medication, unrealistic patient expectations, difficult relationship dynamics, severe performance anxiety, and other psychological problems. Physicians must address these issues to identify true treatment failures attributable to the drugs. This article discusses factors that might affect the response to PDE5 inhibitors and develops a strategy to maximize the overall efficacy of PDE5 inhibitors in initial non-responders to PDE5 inhibitors.
authors: Department of Urology, Pusan National University School of Medicine, Busan, Korea. ; Medical Rresearch Iinstitute, Pusan National University Hospital, Busan, Korea.
authors: Nam Cheol
authors: NC
authors: Park
authors: Tae Nam
authors: TN
authors: Kim
authors: Hyun Jun
authors: HJ
authors: Park
keywords: Erectile dysfunction; Phosphodiesterase type 5 inhibitors; Sildenafil; Tadalafil; Vardenafil
references: Int J Clin Pract. 2006 Aug;60(8):967-75
references: 16780568
references: Int J Impot Res. 2010 Jan-Feb;22(1):51-60
references: 19865092
references: J Clin Endocrinol Metab. 2006 Jun;91(6):1995-2010
references: 16720669
references: J Sex Med. 2004 Nov;1(3):292-300
references: 16422959
references: Andrologia. 2006 Apr;38(2):61-8
references: 16529577
references: Int J Impot Res. 2006 Jul-Aug;18(4):400-4
references: 16395321
references: Eur Urol. 2006 Jul;50(1):126-32; discussion 132-3
references: 16564127
references: Int J Impot Res. 2002 Feb;14 Suppl 1:S43-52
references: 11850735
references: Endocrinology. 1999 Apr;140(4):1861-8
references: 10098525
references: J Urol. 2007 Jun;177(6):2267-71
references: 17509338
references: Urol J. 2009 Fall;6(4):267-71
references: 20027555
references: Endocrinology. 2004 May;145(5):2253-63
references: 14764637
references: J Sex Med. 2011 Jan;8(1):284-93
references: 20704642
references: J Sex Med. 2005 Jul;2(4):559-64
references: 16422854
references: Eur Urol. 2005 Apr;47(4):518-22; discussion 522-3
references: 15774252
references: J Androl. 2001 Sep-Oct;22(5):793-7
references: 11545291
references: J Urol. 2004 Aug;172(2):658-63
references: 15247755
references: Scand J Urol Nephrol. 2008;42(5):437-40
references: 18609275
references: Eur Urol. 2005 Feb;47(2):214-20; discussion 220-2
references: 15661417
references: Clin Endocrinol (Oxf). 2003 May;58(5):632-8
references: 12699447
references: Urology. 2001 Jan;57(1):146-50
references: 11164161
references: J Sex Med. 2008 Jun;5(6):1443-50
references: 18208503
references: Diabetes Care. 2005 May;28(5):1201-3
references: 15855589
references: Eur Urol. 2005 Dec;48(6):996-1002; discussion 1002-3
references: 16174548